Immuron continued its winning streak on Tuesday after the company announced that its IMM-124E has demonstrated neutralizing activity against the severe acute respiratory syndrome due to the virus that causes COVID-19.
Sorrento Therapeutics has announced that its treatment for COVID-19 had cleared its Phase 2 study in hospitalized patients with moderate to severe coronavirus infections.
BioNTech and Pfizer are leading the pack of COVID-19 vaccine stocks as this collaboration came out with more positive news regarding their ongoing German Phase 1/2 study.
As the COVID-19 pandemic continues around the world, and the number of cases in the United States rises relentlessly, there are now three countries that have over a million confirmed cases.
These four sizzling biotech stocks trading under the $10 level have big upside to the analysts' price targets. All of them are rated Buy at Goldman Sachs.
The number of COVID-19 cases continues to rise, which will only create more demand for coronavirus stocks. 24/7 Wall Street has picked out a few of the best and brightest that could still see…
Moderna made another big step forward in the fight against COVID-19 after the company reported incredibly positive data from the early-stage trial of its coronavirus vaccine.